サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1565125

ヘモグロビン異常症の世界市場

Hemoglobinopathies

出版日
ページ情報
英文 192 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ヘモグロビン異常症の世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヘモグロビン異常症の世界市場は2030年までに15億米ドルに達する見込み

2023年に9億960万米ドルと推定されるヘモグロビン異常症の世界市場は、2023年から2030年にかけてCAGR 7.1％で成長し、2030年には15億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである病院の最終用途は、CAGR 7.5%を記録し、分析期間終了時には6億7,640万米ドルに達すると予測されています。診断研究所の最終用途セグメントの成長率は、分析期間中CAGR 7.0%と推定されます。

米国市場は2億4,970万米ドルと推定、中国はCAGR6.6%で成長すると予測

米国のヘモグロビン異常症市場は、2023年に2億4,970万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 6.6%で推移し、2030年には2億2,720万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.9%と5.6%と予測されています。欧州では、ドイツがCAGR 5.7%で成長すると予測されています。

世界のヘモグロビン異常症市場- 主要動向と促進要因のまとめ

ヘモグロビン症は世界保健において見落とされている課題なのか？

ヘモグロビン異常症は、ヘモグロビンの構造や産生に影響を及ぼす遺伝性の血液疾患群であるが、なぜ世界ヘルスにおいて非常に重要なのだろうか？赤血球中の酸素運搬タンパク質であるヘモグロビンは、肺から全身の組織に酸素を届けるために不可欠です。鎌状赤血球症（SCD）やサラセミアなどのヘモグロビン異常症は、ヘモグロビンの機能や構造を変化させ、深刻な健康合併症を引き起こします。これらの疾患は、アフリカ、中東、南アジア、地中海沿岸などの地域で特によく見られ、遺伝性のヘモグロビン変異はマラリアから身を守る利点があるため、広く普及しています。

ヘモグロビン異常症に罹患した人の症状は、慢性的な痛み、重度の貧血、臓器障害、感染症にかかりやすくなるなど、軽度なものから生命を脅かすものまで様々です。例えば、鎌状赤血球症は、赤血球が三日月型になり、血管の閉塞を引き起こし、組織への酸素供給が減少します。一方、サラセミアはヘモグロビンの産生が不十分で、慢性貧血を引き起こし、定期的な輸血を必要とします。これらの疾患は生涯にわたるものであり、しばしば継続的な管理が必要となるため、早期診断と包括的ケアの重要性が強調されています。ヘモグロビン異常症に対する認識が高まるにつれ、特に診断ツールや治療へのアクセスが制限されがちな中低所得国において、これらの疾患は公衆衛生上の重要な課題として認識されるようになってきています。

技術はどのようにヘモグロビン異常症の診断と管理を進歩させたか？

診断技術の進歩は、ヘモグロビン異常症の発見と管理に革命をもたらし、これらの障害を早期に発見し、患者の予後を改善することを容易にしました。従来、ヘモグロビン異常症の診断は、全血球算定（CBC）やヘモグロビン電気泳動などの基本的な血液検査に頼っていました。しかし、最近の遺伝子検査や分子診断学の動向は、ヘモグロビン異常症の診断精度を大幅に向上させています。DNAベースの検査によって、鎌状赤血球症やサラセミアなどの疾患の原因となる特定の変異を特定できるようになり、新生児であっても、より早く、より正確に発見できるようになった。

最も重要な進歩のひとつは、新生児スクリーニング・プログラムの実施であり、高速液体クロマトグラフィー（HPLC）やタンデム質量分析を用いて、新生児のヘモグロビン異常症を検出します。このようなスクリーニングによる早期診断により、ワクチン接種、抗生物質の予防投与、家族へのカウンセリングなど、タイムリーな介入が可能となり、重篤な合併症を予防し、罹患児の長期的な生活の質を向上させることができます。さらに、出生前遺伝学的検査が利用できるようになったことで、親は自分の子孫にヘモグロビン異常症が受け継がれるリスクを評価できるようになり、家族計画を立てる上で重要な情報が得られるようになった。

治療に関しては、遺伝子治療のような技術がヘモグロビン異常症を管理する有望な可能性を示しています。CRISPR-Cas9のような遺伝子編集技術は、鎌状赤血球症やサラセミアのような疾患の根底にある遺伝子変異を修正することで、潜在的な治療法として研究されています。骨髄移植を含む幹細胞治療の進歩も、一部の患者、特にこれらの疾患の重症型患者に治癒の選択肢を提供しています。これらの治療法はまだ開発中であったり、利用可能なものが限られていたりするが、ヘモグロビン異常症の管理における新たなフロンティアであり、将来的にはより効果的で治癒の可能性のある治療法として期待されています。

なぜヘモグロビン異常症の早期診断と早期管理が重要なのか？

ヘモグロビン異常症の早期診断と早期管理は、合併症を大幅に減少させ、罹患者の生活の質を向上させる介入を可能にするため、非常に重要です。鎌状赤血球症の患者にとって、早期診断により、定期的な輸血、疼痛管理、臓器障害を予防する治療などの積極的な管理戦略が可能になります。多くの場合、早期介入により、脳卒中、急性胸部症候群、重症感染症などの生命を脅かす合併症のリスクを減らすことができます。さらに、新生児スクリーニングプログラムは、症状が出る前に鎌状赤血球症の子供を発見するのに非常に効果的であることが証明されており、生命を脅かす感染症から身を守る抗生物質や予防接種を早期に使用することができます。

同様に、サラセミア患者においても、早期診断により、ヘルスケアプロバイダーは定期的な輸血と鉄キレート療法を実施することができ、この疾患に伴う重度の貧血を管理することができます。治療を行わなければ、サラセミアは発育遅延や臓器障害を引き起こし、生命予後が著しく短くなる可能性があります。しかし、適切な管理を行えば、多くのサラセミア患者はより健康で長生きすることができます。鎌状赤血球症もサラセミアも、専門的な治療、遺伝カウンセリング、家族教育を早期に受けることが、これらの複雑な疾患を生涯にわたって管理するために不可欠です。

早期診断の重要性は、個々の患者の転帰にとどまらないです。より大きなスケールでは、ヘモグロビン異常症を早期に発見し管理することで、費用のかかる救急外来受診、入院、長期合併症を予防し、ヘルスケアシステムの負担を軽減することができます。ヘモグロビン異常症が蔓延している地域では、新生児スクリーニングや出生前検査による早期発見に焦点を当てた公衆衛生イニシアチブをとることで、死亡率を下げ、罹患者の全体的な健康状態を改善することができます。意識が高まるにつれ、政府やヘルスケアプロバイダーは、特に医療資源が限られている地域において、ヘモグロビン異常症の包括的なスクリーニングと治療プログラムの必要性を認識するようになってきています。

ヘモグロビン異常症診断・治療市場の成長を促す要因とは？

ヘモグロビン異常症診断・治療市場の成長は、遺伝子検査の進歩、これらの疾患に対する認識の高まり、ヘモグロビン異常症の世界の有病率の上昇など、いくつかの重要な要因によって牽引されています。最も重要な促進要因のひとつは、ヘモグロビン異常症が世界各地で公衆衛生上の重大な懸念事項として認識されつつあることです。世界保健機関（WHO）によると、ヘモグロビン異常症は世界的に最も一般的な遺伝性疾患の一つであり、鎌状赤血球症やサラセミアは数百万人に影響を及ぼしています。罹患地域のヘルスケアシステムが改善されるにつれ、より優れた診断ツールや治療オプションに対する需要が急速に高まっています。

遺伝子検査技術の進歩も市場の成長に寄与しています。出生前スクリーニングやヘモグロビン異常症の早期診断のために、より正確なDNAベースの新しい検査が開発されており、家族に健康リスクに関する重要な情報を提供しています。新生児スクリーニング・プログラムの拡大とともに、こうした検査が利用可能になりつつあることが、より高度な診断ソリューションに対する需要を促進しています。ヘモグロビン異常症が広く普及している地域では、政府はスクリーニングへのアクセスを拡大し、早期診断を改善するための公衆衛生イニシアチブに投資しており、この分野の成長をさらに促進しています。

遺伝子治療や骨髄移植といった革新的な治療法の台頭も、市場拡大を後押しする要因の一つです。輸血や鉄キレート療法のような伝統的な治療がサラセミアのような疾患を管理するための標準であることに変わりはないが、ヘモグロビン異常症の根本的な遺伝的原因をターゲットとする最先端の治療法は、より永続的な解決策の可能性を提供しています。CRISPRのような遺伝子編集技術の研究は、鎌状赤血球症やサラセミアに対する根治的治療法の開発を期待し、この分野に大きな関心と投資を生み出しています。これらの治療法が臨床試験を経てより広く利用できるようになれば、ヘモグロビン異常症の治療状況に革命をもたらすことが期待されます。

技術の進歩に加え、ヘルスケアプロバイダーや一般市民のヘモグロビン異常症に対する認知度の向上も市場の成長に寄与しています。医療従事者と一般住民の双方を対象とした教育的イニシアチブは、これらの疾患の早期診断と適切な管理の重要性に対する認識を高めるのに役立っています。ヘモグロビン異常症が流行している地域では、ヘルスケアプロバイダーがこれらの疾患の症状や危険因子を認識するためのトレーニングを受ける機会が増えており、よりタイムリーな紹介や患者の転帰の改善につながっています。このような意識の高まりは、有病率の高い地域と世界の両方において、より包括的な診断・治療ソリューションに対する需要を促進しています。

最後に、ヘモグロビン異常症を持つ人々のケアへのアクセスを改善することに焦点を当てた政府の取り組みや国際的なパートナーシップが、市場の拡大に重要な役割を果たしています。WHOをはじめとする世界の保健機関は、新生児スクリーニング・プログラムの実施、治療へのアクセスの改善、こうした疾患に対する意識の向上などを目指し、各国政府と協力しています。世界規模でヘモグロビン異常症への取り組みが拡大し続ける中、革新的な診断法、治療法、支持療法への需要が高まり、ヘモグロビン症関連ヘルスケアソリューション市場のさらなる成長が見込まれます。

調査対象企業の例（注目の38社）

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Mindray Medical International Ltd.
  • Nexcelom Bioscience LLC
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP12343

Global Hemoglobinopathies Market to Reach US$1.5 Billion by 2030

The global market for Hemoglobinopathies estimated at US$909.6 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2023-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$676.4 Million by the end of the analysis period. Growth in the Diagnostics Laboratories End-Use segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$249.7 Million While China is Forecast to Grow at 6.6% CAGR

The Hemoglobinopathies market in the U.S. is estimated at US$249.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$227.2 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Hemoglobinopathies Market - Key Trends and Drivers Summarized

Are Hemoglobinopathies the Overlooked Challenge in Global Health?

Hemoglobinopathies are a group of inherited blood disorders that affect the structure or production of hemoglobin, but why are they so crucial in global health? Hemoglobin, the oxygen-carrying protein in red blood cells, is essential for delivering oxygen from the lungs to tissues throughout the body. Hemoglobinopathies, such as sickle cell disease (SCD) and thalassemia, alter the function or structure of hemoglobin, leading to serious health complications. These disorders are particularly common in regions such as Africa, the Middle East, South Asia, and the Mediterranean, where inherited hemoglobin mutations are prevalent due to the protective advantage they provide against malaria.

For individuals affected by hemoglobinopathies, symptoms range from mild to life-threatening, including chronic pain, severe anemia, organ damage, and increased susceptibility to infections. Sickle cell disease, for instance, causes red blood cells to become crescent-shaped, leading to blockages in blood vessels and reduced oxygen delivery to tissues. Thalassemia, on the other hand, results in inadequate production of hemoglobin, causing chronic anemia and requiring regular blood transfusions. These conditions are lifelong and often require ongoing management, highlighting the importance of early diagnosis and comprehensive care. As awareness of hemoglobinopathies grows, they are increasingly recognized as significant public health challenges, particularly in low- and middle-income countries where access to diagnostic tools and treatment can be limited.

How Has Technology Advanced the Diagnosis and Management of Hemoglobinopathies?

Advancements in diagnostic technology have revolutionized the detection and management of hemoglobinopathies, making it easier to identify these disorders early and improve patient outcomes. Traditionally, diagnosing hemoglobinopathies relied on basic blood tests such as a complete blood count (CBC) and hemoglobin electrophoresis, which could indicate abnormal hemoglobin patterns. However, recent developments in genetic testing and molecular diagnostics have greatly enhanced the precision of hemoglobinopathy diagnoses. DNA-based tests can now identify specific mutations responsible for conditions like sickle cell disease and thalassemia, allowing for earlier and more accurate detection, even in newborns.

One of the most significant advancements is the implementation of newborn screening programs, which use high-performance liquid chromatography (HPLC) or tandem mass spectrometry to detect hemoglobinopathies in infants. Early diagnosis through these screenings allows for timely interventions, such as vaccination, antibiotic prophylaxis, and family counseling, that can prevent serious complications and improve the long-term quality of life for affected children. Additionally, the availability of prenatal genetic testing has enabled parents to assess the risk of passing on hemoglobinopathies to their offspring, providing important information for family planning.

In terms of treatment, technologies like gene therapy are showing promising potential for managing hemoglobinopathies. Gene-editing technologies, such as CRISPR-Cas9, are being explored as a potential cure for conditions like sickle cell disease and thalassemia by correcting the underlying genetic mutations. Advances in stem cell therapy, including bone marrow transplants, have also provided curative options for some patients, particularly those with severe forms of these disorders. While these treatments are still in development or limited in availability, they represent a new frontier in the management of hemoglobinopathies, offering hope for more effective and potentially curative interventions in the future.

Why Is Early Diagnosis and Management of Hemoglobinopathies Critical?

Early diagnosis and management of hemoglobinopathies are critical because they allow for interventions that can significantly reduce the complications and improve the quality of life for affected individuals. For patients with sickle cell disease, early diagnosis enables proactive management strategies such as regular blood transfusions, pain management, and treatments to prevent organ damage. In many cases, early interventions can reduce the risk of life-threatening complications such as stroke, acute chest syndrome, and severe infections. Additionally, newborn screening programs have proven highly effective in identifying children with sickle cell disease before symptoms develop, allowing for early use of antibiotics and vaccinations that protect against life-threatening infections.

Similarly, in patients with thalassemia, early diagnosis allows healthcare providers to implement regular blood transfusions and iron chelation therapy, which helps manage the severe anemia associated with the condition. Without treatment, thalassemia can lead to growth delays, organ damage, and a significantly shortened life expectancy. However, with proper management, many patients with thalassemia can lead healthier, longer lives. For both sickle cell disease and thalassemia, early access to specialized care, genetic counseling, and family education is essential for managing these complex disorders over a lifetime.

The importance of early diagnosis extends beyond individual patient outcomes. On a larger scale, identifying and managing hemoglobinopathies early can reduce the burden on healthcare systems by preventing costly emergency room visits, hospitalizations, and long-term complications. In regions where hemoglobinopathies are prevalent, public health initiatives that focus on early detection through newborn screening and prenatal testing can help lower mortality rates and improve the overall health of affected populations. As awareness grows, governments and healthcare providers are increasingly recognizing the need for comprehensive screening and treatment programs for hemoglobinopathies, especially in areas with limited healthcare resources.

What Factors Are Driving the Growth of the Hemoglobinopathies Diagnostics and Treatment Market?

The growth of the hemoglobinopathies diagnostics and treatment market is driven by several key factors, including advancements in genetic testing, increasing awareness of these disorders, and the rising global prevalence of hemoglobinopathies. One of the most significant drivers is the growing recognition of hemoglobinopathies as a major public health concern in many parts of the world. According to the World Health Organization (WHO), hemoglobinopathies are among the most common inherited disorders globally, with sickle cell disease and thalassemia affecting millions of people. As healthcare systems in affected regions improve, the demand for better diagnostic tools and treatment options is increasing rapidly.

Advancements in genetic testing technologies are also contributing to market growth. New, more accurate DNA-based tests are being developed for prenatal screening and early diagnosis of hemoglobinopathies, providing families with critical information about their health risks. The growing availability of these tests, along with expanded newborn screening programs, is driving demand for more advanced diagnostic solutions. In regions where hemoglobinopathies are highly prevalent, governments are investing in public health initiatives to expand access to screening and improve early diagnosis, further fueling growth in this area.

The rise of innovative treatment options, such as gene therapy and bone marrow transplants, is another factor propelling market expansion. While traditional treatments like blood transfusions and iron chelation therapy remain the standard for managing conditions like thalassemia, cutting-edge therapies that target the underlying genetic causes of hemoglobinopathies offer the potential for more lasting solutions. Research into gene-editing technologies, such as CRISPR, has generated significant interest and investment in the field, with the hope of developing curative treatments for sickle cell disease and thalassemia. As these therapies advance through clinical trials and become more widely available, they are expected to revolutionize the treatment landscape for hemoglobinopathies.

In addition to technological advancements, increased awareness of hemoglobinopathies among healthcare providers and the public is contributing to market growth. Educational initiatives aimed at both medical professionals and the general population are helping to raise awareness about the importance of early diagnosis and proper management of these conditions. In regions where hemoglobinopathies are endemic, healthcare providers are increasingly trained to recognize the symptoms and risk factors for these disorders, leading to more timely referrals and better patient outcomes. This growing awareness is driving demand for more comprehensive diagnostic and treatment solutions, both in high-prevalence regions and globally.

Lastly, government initiatives and international partnerships focused on improving access to care for people with hemoglobinopathies are playing a crucial role in expanding the market. Organizations like the WHO and other global health bodies are working with local governments to implement newborn screening programs, improve access to treatments, and raise awareness about these conditions. As efforts to address hemoglobinopathies on a global scale continue to grow, the demand for innovative diagnostics, treatment options, and supportive care is expected to increase, driving further growth in the market for hemoglobinopathy-related healthcare solutions.

Select Competitors (Total 38 Featured) -

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Mindray Medical International Ltd.
  • Nexcelom Bioscience LLC
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Hemoglobinopathies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Genetic Blood Disorders Propels Demand for Hemoglobinopathies Diagnostics and Treatments
    • Growth in Neonatal Screening Programs for Hemoglobinopathies Expands Addressable Market
    • Growth in Adoption of Prenatal Screening for Hemoglobinopathies Strengthens Business Case for Diagnostics
    • Expansion of Advanced Therapies and Gene-based Treatments for Sickle Cell Disease and Thalassemia Fuels Market Growth
    • Growth in Demand for Blood Transfusion and Chelation Therapy in Hemoglobinopathy Patients Fuels Market Expansion
    • Role of Stem Cell Transplantation in Offering Curative Options for Severe Hemoglobinopathies Drives Market Growth
    • Increasing Focus on Gene Therapy and CRISPR-based Approaches Bodes Well for Future Market Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hemoglobinopathies Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hemoglobinopathies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hemoglobinopathies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hemoglobinopathies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Diagnostics Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Beta Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Alpha Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • JAPAN
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • CHINA
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • EUROPE
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hemoglobinopathies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hemoglobinopathies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • FRANCE
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • GERMANY
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2024 & 2030

IV. COMPETITION